Joe Jimenez

Latest Headlines

Latest Headlines

Novartis workers end strike, but vow to fight on

The good news for Novartis ($NVS): Workers in Nyon, Switzerland, have ended their strike. The not-so-good: If union leaders and employees think the drugmaker isn't negotiating in good faith, they'll

Novartis staffers stop work at Nyon plant in jobs protest

Swiss workers haven't taken Novartis' ($NVS) job-cutting plans lying down. First, union members and political activists joined protests in Basel--including one at Chairman Daniel Vasella's (photo)

Novartis cost push claims 2,000 jobs in U.S., Switzerland

Novartis ($NVS) has put a number to its job-cutting plans. The Swiss-based drugmaker will shed 2,000 jobs in its home country and the U.S., while shutting down expensive-to-operate European

Novartis chops 2,000 drug development jobs in shift to Asia

With Joe Jimenez at the helm, Novartis ($NVS) has consistently vowed to back its multibillion-dollar R&D empire, avoiding the wholesale restructuring that has upended research operations at many

Want to impress Novartis' CEO? Don't do it in PowerPoint

Novartis ($NVS) CEO Joe Jimenez (photo) tells the New York Times a few things: He's more patient than he used to be. He's learned how to open the door to bad news. And he's not one to compliment a

CEO: Novartis cost cuts to target sales, manufacturing

Fresh off his promises that this year's round of cost-cutting would top last year's $1.9 billion, Novartis ($NVS) CEO Joe Jimenez (photo) gave the Swiss newspaper Handelszeitung some hints about what

Novartis CEO eyes growth strategies for Alcon

Novartis ($NVS) CEO Joe Jimenez (photo) told Reuters in an interview about his plans for the company's new eye-care division Alcon, which include broader use of implanted lenses and a larger presence

Jimenez aims to keep off-patent Diovan in blockbuster territory

Yesterday, we got some hints about Pfizer's post-patent strategy for Lipitor. Novartis ($NVS) CEO Joe Jimenez (photo) is also thinking patents. He's now talking about his company's post-patent plans

Novartis' interest in buying Gen-Probe fizzles, WSJ reports

Novartis' appetite for deals is expected to grow in the near future, but the Swiss drug giant ($NVS) may no longer be interested in gobbling up diagnostic test provider Gen-Probe. After speculation

Novartis Q2 shines on new meds, cost cuts

Novartis ($NVS) kicked off Big Pharma's earnings release with a nice surge in profits. Sales grew by 27% to $14.9 billion, including an 8% increase at the pharma unit. Profits rose by 12%. The strong